Fundz

Who to call at Inhibitor Therapeutics, and when

Fundz watches for the moments Inhibitor Therapeutics starts buying, and tells you who to reach.

  • An alert the day Inhibitor Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Inhibitor Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Inhibitor Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Inhibitor Therapeutics Enters Performance-Based Master Services Agreement with Frameshift Management

Oct 27, 2025

Contract Type

consulting_agreement

TampaBiotechnologyHealthcareHealth CareMedicalTherapeuticspharmaceuticals

Description

On October 21, 2025, Inhibitor Therapeutics, Inc. entered into a performance-based master services agreement with Frameshift Management, Inc. The Consultant will provide services in biostatistics, regulatory, business development, and strategic consulting to aid the Company's programs for basal cell carcinomas in Gorlin’s syndrome. The agreement includes provisions for equity compensation subject to specific performance requirements.

Quick answer

Inhibitor Therapeutics Enters Performance-Based Master Services Agreement with Frameshift Management (October 27, 2025). Inhibitor Therapeutics is based in Tampa, Florida, United States.

What agreement did Inhibitor Therapeutics announce on October 27, 2025?
On October 21, 2025, Inhibitor Therapeutics, Inc. entered into a performance-based master services agreement with Frameshift Management, Inc. The Consultant will provide services in biostatistics, regulatory, business development, and strategic consulting to aid the Company's programs for basal cell carcinomas in Gorlin’s syndrome. The agreement includes provisions for equity compensation subject to specific...
What does Inhibitor Therapeutics do?
Currently the first line treatment for BCCs on exposed areas such as the face and neck is Mohs Surgery which becomes increasingly challenging and leads to permanent scarring and disfiguration.
Where is Inhibitor Therapeutics based?
Inhibitor Therapeutics is based in Tampa, Florida, United States.

Source: Fundz verified event record.

Company Information

Company

Inhibitor Therapeutics

Location

4830 W Kennedy Blvd

Tampa, Florida, United States

About

Currently the first line treatment for BCCs on exposed areas such as the face and neck is Mohs Surgery which becomes increasingly challenging and leads to permanent scarring and disfiguration. As patients age as they may undergo hundreds of surgeries. Inhibitor believes that itraconazole has clinically meaningful effects on the BCCs, which led us to recruit a team of five experienced Mohs surgeons to form a Scientific Advisory Board (SAB) to critically review the outcomes of Inhibitor's phase 2b trial in BCCNS. They are academically affiliated, well-respected leaders in the practice of treating basal cell carcinomas and other skin cancers The purpose of the SAB is to assess the clinical benefits of adding itraconazole to the therapeutic options for the basal cell carcinomas in these patients. Dr. Sean R. Christensen, MD, PhD. is an Associate Professor of Dermatology; Director of Resident Education in Dermatologic Surgery; Director of Dermatologic Surgery at Yale Dermatology-Branford. Dr. Christensen has been practicing dermatologic surgery since completing training in 2013. His surgical specialization includes Mohs surgery, treatment of early-stage melanoma, and surgical reconstruction. Additionally, Dr. Christensen focuses on complex skin cancer issues such as field characterization, preventative strategies in high-risk patients and management of advanced or aggressive skin cancer. Dr. Christensen has published extensively on skin cancer pathogenesis and treatment and has experience in clinical trials for basal cell carcinoma. He is a frequent lecturer at national meetings for organizations such as the American Academy of Dermatology and the American College of Mohs surgery, and currently serves as the Treasurer for the International Transplant Skin Cancer Collaborative. For more information about Inhibitor and our mission please visit us on our website (www.inhibitortx.com)  and for any further or specific queries you may have please visit our contact us page, submit your details/query, and a representative will be happy to get in touch.

Predictive Intelligence
Strategic

ML-powered predictions for Inhibitor Therapeutics's next move

Learn about Strategic plan

Inhibitor Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.